液体活检在许多不同的癌症中已经被证明具有诊断和预后价值，在乳腺癌中，它们有潜力通过在患者的癌症旅程中提供有价值的信息来改善预后。然而，由于发现和利用强大生物标志物时的局限性，三阴性乳腺癌（TNBC）患者很少从这样的液体活检中获益。在这里，我们研究了基于DNA甲基化的乳腺癌液体活检检测的发展，并探讨其与TNBC相关性。我们对乳腺癌液体活检进行了系统的评估，并分析了它们在TNBC中的相关性，发现基于DNA变异的检测方法在TNBC中的实用性较差，因为这个亚型的基因组突变频率较低。我们提供了对一种针对TNBC患者评估肿瘤负担的液体活检mDETECT的详细评估。DNA甲基化是肿瘤演化中基础且强大的事件，可以区分几乎所有形式的癌症，包括TNBC。使用基于DNA甲基化的液体活检进行患者长期监测具有极大的潜力来改善TNBC的检测和管理。

Liquid biopsies are proving to have diagnostic and prognostic value in many different cancers, and in breast cancer they have the potential to improve outcomes by providing valuable information throughout a patient's cancer journey. However, patients with triple negative breast cancer (TNBC) have received little benefit from such liquid biopsies due to underlying limitations in the discovery and utility of robust biomarkers. Here, we examine the development of DNA methylation-based liquid biopsy assays for breast cancer and how they pertain to TNBC.We conducted a systematic review of liquid biopsy assays for breast cancer and analyzed their relevance in TNBC. We show that the utility of DNA mutation-based assays is poor for TNBC due to the low mutational frequencies across the genome in this subtype. We offer a detailed review of mDETECT - a liquid biopsy specifically designed for assessing tumor burden in TNBC patients.DNA methylation are foundational and robust events that occur in cancer evolution and may differentiate almost all forms of cancer, including TNBC. Longitudinal patient monitoring using DNA methylation-based liquid biopsies offers great potential for improving the detection and management of TNBC.